Remove Doctors Remove Protein Expression Remove Protein Production Remove Therapies
article thumbnail

Driving efficiency across upstream bioprocess workflow

Drug Target Review

As discussed above, recent advances in gene editing tools and transposon-based vectors have facilitated targeted and consistent cell line engineering for the development of protein expressing CHO cell lines. Cell Gene Therapy Insights 2017; 3(2), 131-158, 10.18609/cgti.2017.014. Budge JD, Knight TJ, Povey J, et al.

article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

These include: Samantha Bailey-Bucktrout, PhD, Senior Vice President, Akamis Bio, on: ‘Tumour specific immunogene therapy to deliver protein therapeutics to solid tumour microenvironments’. Alessa Schaffrath, Doctoral Student, UKE Hamburg, on: ‘Transgenic llama mice – a fast and flexible single domain discovery tool’.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

Yuchih Lin, Doctor, Sino Biological Europe, on: ‘Accelerating drug discovery using advanced antibody development platforms’. Christopher Rowley, PhD, Principal Research Scientist, Protein Science Pipeline, Immunocore, on: ‘ImmTAC: A high-affinity soluble TCR bispecific platform to target cancers’.

article thumbnail

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

The Pharma Data

An initial analysis of data from 17/22 patients who completed one of these assessments showed substantially decreased neurocognitive abilities compared to children of the same age level despite the use of multiple anti-epileptic therapies. .–( BUSINESS WIRE )– Stoke Therapeutics , Inc. STK-001 is designed to upregulate Na V 1.1